Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tempus AI, Inc. Class A (TEM)
NASDAQ:TEM
Holding TEM?
Track your performance easily
TEM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$22.89 - $79.49
Previous Close$62.59
Volume445.12K
Average Volume (3M)1.16M
Market Cap
$9.85B
Enterprise Value$9.86B
Total Cash (Recent Filing)$466.32M
Total Debt (Recent Filing)$471.55M
Price to Earnings (P/E)―
Beta5.58
Next Earnings
Aug 12, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding157,445,683
10 Day Avg. Volume1,750,075
30 Day Avg. Volume1,157,491
Standard Deviation0.27
R-Squared0.51
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)171.03
Price to Sales (P/S)26.01
Price to Cash Flow (P/CF)43.70
P/FCF Ratio33.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue30.18
Enterprise Value/Gross Profit34.45
Enterprise Value/Ebitda-109.36
Forecast
1Y Price Target
$58.29Price Target Upside-6.87% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Tempus AI, Inc. Class A News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe Data & Services segment outperformed expectations, driven predominantly by the Insights business, which grew 87% year-over-year.
Growth OpportunitiesTempus AI's genomics business is the fastest growing and largest by test volumes, with expectations of strong growth and rising margins.
Strategic AcquisitionThe acquisition of Ambry makes strategic sense by adding significant germline testing presence and facilitating entry into new tests and data types.
Bears Say
Growth ExpectationsCommentary from a recent conference call suggested that the 2025 outlook for the core Tempus business could be guided below expectations next quarter.
Market Growth RateThe Ambry Genetics contribution will make the combined business EBITDA and cash flow positive on a run-rate basis, but the top-line growth rate of Ambry's assets is expected to be dilutive to Tempus given the slower growth profile of the hereditary cancer testing market.
Valuation ConcernsThe stock is up ~100% since its debut, but valuation now sits well above key peers, with shares sitting at 12.5x '25 sales compared to NTRA at 9.4x and GH at 4.6x.
---
Ownership Overview
51.55% Insiders
2.71% Mutual Funds
18.23% Other Institutional Investors
24.86% Public Companies and Individual Investors
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $22.89 and its highest was $79.49 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Currently, no data Available
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
Tempus AI, Inc. Class A’s upcoming earnings report date is Aug 12, 2025 which is in 236 days.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Tempus AI, Inc. Class A released its earnings results on Nov 04, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.266 by $0.016.
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Overvalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tempus AI, Inc. Class A have?
Tempus AI, Inc. Class A has 152,401,900 shares outstanding.
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Tempus AI, Inc. Class A reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.266. Following the earnings report the stock price went down -10.101%.
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Among the largest hedge funds holding Tempus AI, Inc. Class A’s share is ARK Investment Management LLC. It holds Tempus AI, Inc. Class A’s shares valued at 135M.
---
Tempus AI, Inc. Class A Stock Smart Score
Company Description
Tempus AI, Inc. Class A
Tempus AI endeavors to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence in healthcare. Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal. To accomplish this, we built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Our proprietary technology has allowed us to amass what we consider to be one of the largest libraries of clinical and molecular oncology data in the world. We have launched a suite of different products derived from our Platform, which have gained significant traction over the past five years. To date, our offerings have been used by approximately 95% of the largest public pharmaceutical companies.
---
TEM Company Deck
---
TEM Earnings Call
Q3 2024
0:00 / 0:00
---
TEM Stock 12 Month Forecast
Average Price Target
$58.29
▼(-6.87% Downside)
Technical Analysis
Best Analysts Covering TEM
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+61.07%
reiterated a buy rating last month
Copying Ryan MacDonald's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +61.07% per trade.
---